METHODS TO INHIBIT CELL GROWTH
A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization.
1 . A method for detecting a protein or polypeptide in a test sample, comprising:
contacting the test sample with an antibody or fragment thereof that specifically binds to SEQ ID NO: 3 or a polynucleotide that specifically binds to SEQ ID NO: 2; and
detecting binding of the antibody or fragment thereof or polynucleotide to a protein or polynucleotide, respectively, in the test sample.
2 . The method of claim 1 , wherein the detection indicates the presence of cancer.
3 . The method of claim 2 , wherein the cancer is selected from the group consisting of lymphoma, leukemia, and cancers of the prostate, testes, kidney, brain, bone, skin, ovary, breast, pancreatic, colon, cervix, uterus, stomach, rectum, and lung.
4 . The method of claim 1 , further comprising:
contacting a normal sample with the antibody or fragment or the polynucleotide that specifically binds to SEQ ID NO: 2; and
detecting an amount or absence of binding of the antibody or fragment or polynucleotide to a protein or polynucleotide, respectively, in the normal sample; and
comparing the amount or absence of binding detected in the normal sample to the binding detected in the test sample.
5 . The method of claim 4 , wherein an elevated amount of binding detected in the test sample relative to the normal sample indicates the presence of cancer.
6 . The method of claim 5 , wherein the cancer is selected from the group consisting of lymphoma, leukemia, and cancers of the prostate, testes, kidney, brain, bone, skin, ovary, breast, pancreatic, colon, cervix, uterus, stomach, rectum, and lung.
7 . The method of claim 1 , wherein the test sample is contacted with the polynucleotide that specifically binds to SEQ ID NO: 2, which polynucleotide comprises an mRNA or a cDNA.
8 . The method of claim 1 , wherein the test sample is taken from a patient with cancer.
9 . The method of claim 1 , wherein the test sample is taken from a tissue selected from the group consisting of prostate, bladder, kidney, colon, lung, pancreas, ovary, breast, uterus, stomach, rectum, cervix, lymph node, blood, and bone.
10 . A method for detecting a protein in a test sample, comprising:
contacting the test sample with an antibody or fragment thereof that specifically binds to SEQ ID NO: 3; and
detecting binding of the antibody or fragment thereof to a protein in the test sample.
11 . The method of claim 10 , further comprising:
contacting a normal sample with the antibody or fragment thereof; and
detecting an amount or absence of binding of the antibody or fragment thereof to a protein in the normal sample; and
comparing the amount or absence of binding detected in the normal sample to the binding detected in the test sample.
12 . The method of claim 11 , wherein an elevated amount of binding detected in the test sample relative to the normal sample indicates the presence of cancer.
13 . The method of claim 12 , wherein the cancer is selected from the group consisting of lymphoma, leukemia, and cancers of the prostate, testes, kidney, brain, bone, skin, ovary, breast, pancreatic, colon, cervix, uterus, stomach, rectum, and lung.
14 . The method of claim 10 , wherein the antibody or fragment thereof is monoclonal.
15 . The method of claim 10 , wherein the antibody or fragment thereof is recombinant.
16 . The method of claim 10 , wherein the antibody or fragment thereof is a single chain monoclonal antibody or an Fab, F(ab′) 2 , Fv or Sfv fragment.
17 . The method of claim 10 , wherein the antibody or fragment thereof is labeled with an agent.
18 . The method of claim 17 , wherein the agent is a radioactive isotope.
19 . The method of claim 18 , wherein the radioactive isotope is selected from the group consisting of 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P and radioactive isotopes of Lu.
20 . The method of claim 10 , wherein the antibody or fragment thereof is a human or humanized antibody.